Results 241 to 250 of about 1,010,901 (298)

m5C Reader ALYREF Promotes the Progression of Endometrial Cancer by Activating the XRCC6‐Mediated Wnt/β‐catenin Signaling Pathway

Advanced Science, EarlyView.
This study identifies ALYREF as an oncogenic m5C reader in endometrial cancer. ALYREF recognizes NSUN2‐mediated m5C modification on XRCC6 mRNA to enhance transcript stability and increase XRCC6 expression. Elevated XRCC6 activates Wnt/β‐catenin signaling, resulting in accelerated tumor cell proliferation, migration, invasion, and xenograft tumor growth.
Linlin Hao, Jian Zhang, Qi Qian, Min Jiang, Yu Liu, Yan Geng, Nan Cui, Qi Guo, Jie Guo   +8 more
wiley   +1 more source

The prostatic inflammation score and risk of biochemical recurrence following radical prostatectomy. [PDF]

World J Urol
Guzzi F, Falagario UG, Cormio A, Ninivaggi A, Finati M, d'Altilia N, Fanelli A, Fiorella RA, Busetto GM, Bettocchi C, Castellani D, Conteduca V, Carrieri G, Sanguedolce F, Cormio L.   +14 more
europepmc   +1 more source

External validation of the European association of urology biochemical recurrence risk groups to predict mortality after radical prostatectomy or radiation therapy in a North American cohort. [PDF]

BJUI Compass
Silvani C, Santangelo A, Stephens A, Considine J, Tinsley S, Salka B, Sood A, Nazzani S, Briganti A, Salonia A, Montorsi F, Nicolai N, Montanari E, Rogers C, Abdollah F.   +14 more
europepmc   +1 more source

Prognostic features of biochemical recurrence of prostate cancer following radical prostatectomy based on diffusion kurtosis imaging. [PDF]

Cancer Imaging
Lin LP, Cheng XW, Chen J, Li SY, Bian J, He JK, Liu DM, Liu QY, Zhou KP.   +8 more
europepmc   +1 more source

PA2G4 in CAFs promotes biochemical recurrence of prostate cancer via H3K18la. [PDF]

Cell Biosci
Ji S, Xi Z, Li T, Jia G, Zhang Y, Zheng C, Wang W, Ni W, Zhang Y, Zhou Z, Wu W, Jiang Q.   +11 more
europepmc   +1 more source

Head-to-Head Comparison of [68Ga]Ga-PSMA-11 PET Interpreted with Non-Contrast CT Versus Excretory-Phase CT Urography in Biochemical Recurrence of Prostate Cancer. [PDF]

Cancers (Basel)
Betech-Antar V, Rosales JJ, Mínguez F, Romera M, Fuertes L, Díez-Caballero F, Miñana-López B, Martinez-Monge R, Guillen EF, Rodríguez-Fraile M.   +9 more
europepmc   +1 more source

A novel prognostic signature based on mitochondrial permeability transition-driven necrosis genes for biochemical recurrence prediction in prostate cancer. [PDF]

Front Oncol
Luo X, Huang Z, Deng M, Liu J, Sun B, Zhu J, Chen Y, Su S, Zhao J, Zheng J.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Salvage therapy at biochemical recurrence of prostate cancer

Nature Reviews Urology, 2020
No clear consensus exists for managing biochemically recurrent prostate cancer after prostatectomy. Interpretation of new data from the JCOG0401 trial warrants consideration of imaging techniques, prostate-specific antigen (PSA) levels at time of salvage radiotherapy (SRT), use of SRT ± salvage androgen deprivation therapy based on PSA levels, and the ...
Nicholas G. Zaorsky, Amar U. Kishan
openaire   +2 more sources